European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drugbenzinga.comPharming's Phase 3 trial results for leniolisib in children with APDS demonstrate efficacy and safety, supporting future regulatory filings in 2025.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesdayinvestorplace.comPre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!
Earnings Scheduled For March 14, 2024benzinga.comCompanies Reporting Before The Bell • Pharming (
NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
What's Going On With Netherlands-Based Biopharma Company Pharming Shares Today?benzinga.comPharming Group (
NASDAQ: PHAR) updated its full-year 2023 guidance, including RUCONEST and Joenja revenues, and a progress update on the
